Arbutus reports 50% functional cure in HBsAg<1000 IU/mL patients with imdusiran + IFN in Phase 2a

Arbutus Biopharma Corp

Cohort A1: 50% (3/6) functional cure in HBeAg-negative patients with baseline HBsAg <1000 IU/mL; overall 25% (3/12).
IM-PROVE II Group C: 23% (3/13) achieved HBsAg loss at Week 48 with imdusiran, VTP-300 and low-dose nivolumab.
Both regimens generally well-tolerated; no imdusiran/IFN-related SAEs or discontinuations in IM-PROVE I.
Data to be presented at AASLD The Liver Meeting 2024 on November 18. Corporate presentation updated on website.
Combination of imdusiran and interferon shows potential for finite curative treatment in chronic HBV.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.